Pharmacokinetic Study of E7080/Lenvatinib in Chinese Patients With Unresectable Hepatocellular Carcinoma (HCC)
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 25 May 2018
At a glance
- Drugs Lenvatinib (Primary)
- Indications Liver cancer
- Focus Pharmacokinetics
- Sponsors Eisai Co Ltd
- 25 May 2018 Planned End Date changed from 1 Jun 2018 to 1 Sep 2018.
- 21 Sep 2017 Status changed from recruiting to active, no longer recruiting.
- 08 Nov 2016 New trial record